Evidence map›Paper›PMID 40605152›Full record

ArticleMicrobiologyOpen2025

Optimization of Medium Composition for High Cell Density Culture of Bifidobacterium longum HSBL001 Using Response Surface Methodology.

Hao Cheng, Jiangbin Liu, Liya Mei, Wei Liu, Fengxi Yang, Xiaojuan Ma, Yan Zhang, Youfa Xie, Yang Zhang, Yanxia Xiong

Abstract read
In one paragraph

Article in MicrobiologyOpen, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. From genetic constraints to process hurdles: A review ofCurrent research in food science · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hao ChengJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.ORCID https://orcid.org/0000-0002-7661-6317
Jiangbin LiuJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.
Liya MeiJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.
Wei LiuJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.
Fengxi YangJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.
Xiaojuan MaJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.
Yan ZhangJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.
Youfa XieJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.
Yang ZhangJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.
Yanxia XiongJiang Zhong Pharmaceutical Co. Ltd., Nanchang, China.

Funding

The authors received no specific funding for this study.
6 · The paper itself

Abstract

Bifidobacterium longum plays a critical role in the human gut and exhibits diverse probiotic functions. Achieving high-density fermentation of B. longum largely depends on the composition of the culture medium and fermentation conditions. This study aimed to optimize the medium composition and fermentation parameters for B. longum HSBL001, using viable cell counts and optical density at 600 nm (OD600) as indicators. The goal was to improve biomass yield and support the development and industrial application of highly active probiotic preparations. The optimal medium composition and culture conditions were established using a combination of single-factor experiments, the Plackett-Burman design, the steepest ascent method, and the central composite design. The optimized culture medium consisted of yeast extract (19.524 g/L), yeast peptone (25.85 g/L), arginine (0.599 g/L), glucose (27.36 g/L), MnSO

Indexed as

Bifidobacterium longumCulture MediaBiomassFermentationHumansHydrogen-Ion ConcentrationProbioticsCulture Mediaanaerobic fermentationBifidobacterium longumhigh cell density culturemedium optimizationresponse surface methodology

Identifiers

PMID40605152
PMCPMC12221998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.